Biotechnology companies have limited resources and may have limited experience in drug development, but are under pressure to demonstrate early proof of concept to enhance company value and attract additional funding. Streamlined, cost efficient preclinical programs need to be developed to minimize the time to IND and to proof of concept in man.
With expertise spanning basic research, preclinical, and clinical development, and experience in working with biotech companies to demonstrate early proof of concept, the Camden Group is uniquely positioned to:
Analyze early pharmacologic data to assist you in directing resources to drug candidates most likely to succeed.
Work from early pharmacologic data to develop nonclinical programs that will satisfy regulatory guidances to open an IND.
Optimize timelines for preclinical and Phase I/ Phase II clinical studies to demonstrate early proof of concept in man. The clinical programs we previously led were at the industry benchmark for speed from First-in-Man to initiation of Phase III.
Click here to see how the Camden Group can help you in the earliest stages of drug development.
